Company intelligence / Profile preview

Pinze Lifetechnology Co. Ltd.

Ownership: Private
Development stage: NDA

Overview

The company has conducted a Phase 1 clinical trial (NCT03281551) to assess the feasibility, safety, and effectiveness of CD19 CAR-T Cell Therapy for Relapsed/Refractory Acute Lymphoblastic Leukemia/B cell Lymphoma patients[1][3]

Therapeutic areas: Oncology
Modalities: CAR-T cell therapy
Industry: Biotech

Drug pipeline

1 asset

inaticabtagene autoleucel

NDA

Indications: B-cell acute lymphoblastic leukemia

Beyond the preview

Go deeper on Pinze Lifetechnology Co. Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pinze Lifetechnology Co. Ltd..

Explore the full profile